Malignant melanomas are capable of producing a wide range of cytokines with multiple biologic functions, including interleukin 6 (IL-6). We have observed an inverse relationship between IL-6 production of three B 16-derived murine melanoma cell lines (NP133, HFH18, and HFH(M)) and the tumorigenicity of these melanoma cells in syngeneic mice. To further test the effect of IL-6 on melanoma growth, a non -IL-6 -producing murine B 16-derived melanoma cell line (HFH18) was transfected with a murine IL-6 expression vector, resulting in stable transfectants (HFH18/ IL-6(+») that expressed significant amounts of IL-6 mRNA and secreted high levels of bioactive IL-6. Syngeneic C57BL/ 6 mice inoculated subcutaneously with HFH18/ IL-6(+) cells developed tumors that reached a final mean diameter of less than half the size of tumors that developed in mice inoculated with either HFH18 parental or HFH18 cells transfected with the IL-6 eDNA in the non-coding 3'-5' orientation (HFH18/IL-6(-) cells). In addition, mice bearing IL-6-M alignant melanoma is a serious neoplasm that accounts for 1-2% of cancer deaths per year in the United States. The incidence of malignant melanoma is increasing more rapidly than that of any other cancer, at the rate of 4% per year, with 32,000 new cases of melanoma expected this year [1] . Early diagnosis and surgical excision of thin primary cutaneous melanoma successfully prevent metastatic progression. However, the response rates of patients with advanced metastatic disease remain low to both standard chemotherapy and immunologically based therapy strategies. Further understanding of the biologic behavior of melanoma cells is necessary to devise more successful treatment approaches for these patients.
Malignant melanomas are capable of producing a wide range of cytokines with multiple biologic functions, including interleukin 6 (IL-6). We have observed an inverse relationship between IL-6 production of three B 16-derived murine melanoma cell lines (NP133, HFH18, and HFH(M)) and the tumorigenicity of these melanoma cells in syngeneic mice. To further test the effect of IL-6 on melanoma growth, a non -IL-6 -producing murine B 16-derived melanoma cell line (HFH18) was transfected with a murine IL-6 expression vector, resulting in stable transfectants (HFH18/ IL-6(+») that expressed significant amounts of IL-6 mRNA and secreted high levels of bioactive IL-6. Syngeneic C57BL/ 6 mice inoculated subcutaneously with HFH18/ IL-6(+) cells developed tumors that reached a final mean diameter of less than half the size of tumors that developed in mice inoculated with either HFH18 parental or HFH18 cells transfected with the IL-6 eDNA in the non-coding 3'-5' orientation (HFH18/IL-6(-) cells). In addition, mice bearing IL-6-M alignant melanoma is a serious neoplasm that accounts for 1-2% of cancer deaths per year in the United States. The incidence of malignant melanoma is increasing more rapidly than that of any other cancer, at the rate of 4% per year, with 32,000 new cases of melanoma expected this year [1] . Early diagnosis and surgical excision of thin primary cutaneous melanoma successfully prevent metastatic progression. However, the response rates of patients with advanced metastatic disease remain low to both standard chemotherapy and immunologically based therapy strategies. Further understanding of the biologic behavior of melanoma cells is necessary to devise more successful treatment approaches for these patients.
The role of cytokines and growth factors in the development and progression of cancer has recently become an active area of cancer research . Melanomas are capable of producing a number of cytokines with multiple biologic functions, including interleukin 6 (IL-6) [2] [3] [4] [5] [6] [7] [8] . The heterogeneity of cytokine production among melanomas and the ability of individual human melanomas to produce multiple cytokines have been recently demonstrated by our group and others [5, 9] . In particular, we have shown that the cytokine profile of two widely used, distinct human melanoma cell lines, A375 and G361, demonstrate marked differences in IL-6 producManuscript received May 14, 1993 ; accepted for publication October 14, 1993 .
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producing HFH18/ IL-6(+) tumors survived twice as long as mice bearing HFH18 parental or HFH18/ IL-6 H tumors. The specificity of melanoma growth inhibition by IL-6 was confirmed by the reversal of the slow-growing phenotype of HFH18/ IL-6(+) cells by local peri tumoral administration of neutralizing a-murine IL-6 antibody. IL-6-producing melanoma cells exerted a growth-inhibitory effect on distant parental tumors in a dose-dependent manner. The growth of HFH18/ IL-6(+) melanomas was also decreased in nude mice, suggesting that melanoma-derived IL-6 may mediate this anti-tumor effect independently of a normal host B-and T-cell immune response. Thus, melanoma-derived IL-6 exerts a significant inhibitory effect on cutaneous melanoma growth and progression. These results indicate that melanoma cytokines may have a profound effect on tumor patho-
genesis. Key words: interleukin-6/melanoma/cytokines. ] Invest
DermatoI102: [278] [279] [280] [281] [282] [283] [284] 1994 tion [5] . Prior observations that IL-6 is produced by a number of hematopoietic as well as solid neoplasms other than melanomas have led to investigations of the role ofIL-6 in tumorigenesis [10] [11] [12] [13] [14] [15] [16] [17] . IL-6 has been shown to have both tumor-promoting as well as anti-tumor effects in various types of tumors studied by different experimental approaches [13] [14] [15] [16] [17] [18] [19] [20] . The importance of specific tumor-derived cytokines in the biology of malignant melanoma is essentially unknown. In this study we have evaluated the effect of tumor-derived IL-6 on the pathogenesis of malignant melanoma in an immunocompetent syngeneic murine host. We report here that melanoma-derived IL-6 can exert a significant inhibitory effect on subcutaneous melanoma growth and progression.
MATERIALS AND METHODS
Melanoma Cell Lines The murine B16-derivcd malignant melanoma cell lines NP133, HFH18, and HFH(M) obtained from Dr. Funan Hu (Oregon Primate Center, Portland, OR) [21, 22) were grown and maintained in Dulbecco's modified Eagle's medium (DMEM) cell culture media (Gibco, Grand Island, NY supplemented with 5% calf serum. Transfected HFH18 cells were cultured in selective tissue culture media supplemented with 0.8 -1.0 mg/ml geneticin (G418).
Bioassay for IL-6 Secreted IL-6 activity was measured in the B9 proliferation bioassay as described previously [5, 23, 24) . Cell proliferation was measured as a function of incorporated 3H thymidine counts per minute ([cpm] ± SEM) in triplicate wells at dilutions ranging from 1: 2 to 1: 1260.
Specificity of this assay was confirmed by inhibiting B9 proliferative activity with neutralizing a-murine IL-6 antibody (R&D Systems, Minneapolis, MN).
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Melanoma Cell Proliferation Assays Melanoma cell lines were plated at a cell concentration of 2 X 10' cells/well in triplicate wells of 24-well plates in DMEM with 1 % calf serum alone, or with lOOI1/m! recombinant murine IL-6 (Biosource International, Camarillo, CAl added every 24 h. In selected experiments, 10 I1g/m! neutralizing a-murine IL-6 antibody (R & D Systems) was added to cultured cells every 48 h. Cells were trypsinized and counted with a hemocytometer and Coulter counter at days I, 3, and 6 to determine the number of cells per well.
Northern Blot Analysis RN A was extracted from murine melanoma cell lines that were cultured as above [5] . Poly A+ mRNA was prepared by the oligo (dT)-cellulose affinity chromatography method as previously described [25] . Northern blot analysis was performed as described previously [5] . The murine IL-6 cDNA probe used in these studies was generously provided by J. van [26] . An 1100-base pair (bp) Eco Rl fragment of pHPIB5 containing the entire mIL-6 cDNA coding sequence was sub cloned into the Bam HI site of pZipNeo SV(X). An asymmetric Bgl II restriction site within the Eco Rl insert was used to orient the resulting plasmids. Plasmids were then constructed with 1) the murine IL-6 cDNA in the 5'-3' orientation for expression ofIL-6 protein and 2) the murine IL-6 cDNA in the 3'-5' orientation, which results in no IL-6 protein synthesis. These TL-6 plasmids as well as pZipNeo SV(X) vector alone were transfected into the non-IL-6 producing HFH18 parental cell line by electroporation. Cells were plated in non-selected media for 48 h, then replated in media containing 1 mg/ml G418. Neomycin-resistant clones were isolated with glass cloning rings after 10 -14 d, expanded in cell culture, and screened for IL-6 production using the B9 IL-6 bioassay. A clone with the IL-6 cDNA in the 5'-3' orientation that secreted significant levels of IL-6 was designated HFH18/IL-6(+) and a clone with the IL-6 cDNA in the 3'-5' orientation that secreted no IL-6 was designated HFH18/IL-6(-) for use in further experiments.
Animals Specific-pathogen-free 6-week-old female C57BL/6 mice or athymic C57BL/6 nu/nu (nude) mice were obtained from Jackson Animal Laboratories (Bar Harbor, ME) and housed in the animal facilities at the Portland Veterans Affairs Medical Center.
Measurement of Tumor Size and Host Survival Cultured murine melanoma cells (NP133, HFH18, HFH(M), or transfected HFH18 cells) were trypsinized when cells approached log-phase growth, washed twice in phosphate-buffered saline (PBS), and resuspended in PBS for injection. The number of viable cells was determined by the trypan blue exclusion method. Suspensions of cells in 0.2 ml PBS were inoculated subcutaneously (sc) into the anterior flank. Tumor mean diameter was determined by measuring tumors of methoxyflurone-anesthetized animals in two perpendicular axes with calipers. Tumor volume was determined by measuring tumors in threc perpendicular diameters with calipers with tumor volume calculated as t X (length X width X height) [27] . Differences in tumor size between groups were determined by a two-way analysis of variance. Differences in survival between groups were dctermined by life table analysis.
Histology and Immunohistochemistry Sections of melanoma tissue were stained with hematoxylin and eosin (H&E) and examined by light microscopy. Immunohistochemistry was performed as previously described with melanoma tissue embedded immediately in OCT and frozen at -80· C [28] . Briefly, tissue was cut into 4-11 frozen sections that were fixed in cold acetone, stained with monoclonal rat a-murine IL-6 antibody (Pharmingen, San Diego, CAl followed by alkaline phosphatase-conjugated rabbit a-rat IgG, and color was developed using fast red TR as substrate. Immunohistochemistry was similarly performed on mono layers of cultured melanoma cells fixed in actone then permeabilized with 0.1 % saponin [28] using monoclonal rat a-murine IL-6 antibody (Pharmingcn) to evaluate IL-6 production and monoclonal rat a-murine IL-6 receptor antibody (Bio Source International) to evaluate IL-6 receptor expression. measured in three perpendicular axes with calipers at 2-d intervals and tumor volume was calculated as above [27] .
RESULTS
Heterogeneity of IL-6 Production and Tumorigenicity in Murine Melanoma Cell Lines Three B 16-derived murine melanoma cell lines (NP133, HFH18, and HFH(M)) were characterized in terms of in vitro IL-6 production and tumorigenicity in syngeneic C57BL/6 mice. The secretion ofIL-6 by these cell lines was measured in the B9 bioassay (Fig 1) . As indicated, the NP133 cell line constitutively secretes significant amounts of IL-6 bioactivity. In contrast, the HFH18 and HFH(M) cell lines do not secrete detectable amounts of IL-6 bioactivity. Parallel differences were noted in mRNA levels (data not shown). The ability of NP133, HFH18.' and HFJ:1(M) murine melanoma cell lines to generate tumors 111 syngeneIc l1uce after subcutaneous inoculation was determined. Mice ino.culated with the IL-6-secreting NP133 cell line develop tumors 111 O!~ly. on~ of 10 treated animals followed up to 60 d after tumor cell 1I1Jectlon (Table I ). In contrast, mice injected with the non:-IL-6-secreting HFH18 and HFH(M) cell lines develop .tumors m 100% of treated animals within 15 d post injection. The smgle tumor that developed in one animal inoculated with the NP133 cell line was approximately one third the size of the HFH18 or HFH(M) mela~omas at d 30 after injection. These results suggest that IL-6 production by murine melanoma cells may be related to decreased tumor growth and progression ill vivo. Because other tumor cell phenotypic differences could also account for differences in me.lanoma tu~origenicity, we generated melanoma cell lines that dIffered only m their ability to produce IL-6. • C57BL/6 mice were inoculated sc in the anterior /lank with 1 X 10' murine melanoma cells. Tumor growth and host survival were detennined (±SD). , All mice were alive at 60 d after tumor cell inoculation. Establishment of IL-6-Producing Melanoma Cell Lines Genetically identical melanoma cell lines that differed only in IL-6 production were established. A murine IL-6 eDNA expression vector was transfected into the non-IL-6 -producing HFH18 melanoma cell line. A transfected clone designated HFHI8/IL-6(+) was found to constitutively secrete high levels ofIL-6 as determined in the B9 IL-6 bioassay and thus was selected for further in vivo studies (Fig 2) . Parental HFH18 cells transfected with the pZipNeoSV vector alone (HFHI8/neo) or with the IL-6 eDNA gene insert in the reverse (3'-5') orientation (HFH 18/IL-6(-») did not secrete IL-6 (Fig 2) . The production ofIL-6 by the HFH18/IL-6(+) cell line was confirmed by immunohistochemistry (data not shown) . The proliferation rate of cultured IL-6-producing melanoma cells does not differ significantly from that of the parental HFH18 cell line or the HFHI8/IL-6(-) line. Additionally, the in vitro proliferation of the parental cell line i. s that developed in animals injected with NP133 cells, HFH18 cells, and HFH18 transfected melanoma cells. HFH18/IL-6(+) tumors stain strongly positive for IL-6 ( Fig SA) . In contrast, little IL-6 staining is detected in HFH18 (Fig 5B) or HFH18/IL-6(-) tumors (data not shown). As a positive control, NP133 tumors that constitutively produce IL-6 in vitro also stain strongly positive for IL-6 ( Fig 5C) . HFHI8/IL-6(+) tumor explants continue to secrete IL-6 bioactivity in tissue culture whereas HFH18 or HFH18/IL-6(-) tumor explants secrete no IL-6 bioactivity in culture (data not shown) . These studies indicate that tumors that develop from injected HFH18/IL-6(+) cells continue to secrete IL-6 in vivo.
Elevated Serum IL-6 in Mice Bearing HFH18/ IL-6(+) Tumors To determine whether local tumor production of IL-6 results in increased serum levels of this cytokine, serum IL-6 levels in mice inoculated with either the HFH18 melanoma cell line or the HFH18 transfected cell lines were measured in the B9 bioassay.
As indicated in Fig 6 , serum IL-6levels of mice developing tumors after injection with HFH18 and HFHI8/IL-6(-) cells are similar to those of mice injected with saline at 5,10, and 15 d after tumor cell injection (Fig 6) . In contrast, serum IL-6 levels in mice developing tumors after inoculation with HFH18/IL-6(+) cells are markedly Figure 6 . Serum IL-6 levels in melanoma-bearing mice. Groups of C57BLj6 mice were inoculated sc with 1 X 10 6 HFH18 parental (e), HFH18jIL-6(-) ("'), or HFH18jIL-6(+) (II) cells. Control mice were injected sc with saline alone at day 0 (0). Serum samples were obtained when mice were euthanized at 5,10, 15, and 30 d after tumor cell injection. Serum IL-6 ~ioactivity was determined by the B9 murine plasmacytoma proliferation blOassay. These data are the average of serum samples from four animals per cell line injected at each time point expressed as unitsjml, with SD indicated by error bars.
d 30 after tumor cell inoculation (Fig 6) . Interestingly, by d 3D, the serum IL-6levels of mice bearing HFH18 or HFH18/IL-6(-) melanomas are also elevated above control animal levels. At this stage the tumor weight of these non -IL-6 -producing tumors is approximately 50% of the weight of the mouse. Increased serum IL-6levels with a large tumor cell burden have been previously reported in various types of neoplasms [29, 30] . The tumor burden of mice bearing small HFH18/IL-6(+) tumors is significantly less than that of mice bearing the significantly larger HFH18 parental or HFH18/ IL-6(-) melanomas at all time points after tumor cell inoculation. In spite of this small tumor size, however, these neoplasms are associated with high levels of serum IL-6. These results indicate that the mice with HFH18/IL-6(+) melanomas have significantly higher levels of serum IL-6 compared to animals with HFH18 or HFH18/ IL-6(-) melanomas (p < 0.01) . scribed neoplasms by d 10. In contrast, the small tumors formed by the HFH18/IL-6(+) cell line are sharply circumscribed and have no evidence of an infiltrative tumor cell pattern. Both IL-6 -producing and non -IL-6 -producing melanomas are associated with a moderately dense peritumoral inflammatory cell infiltrate composed primarily of lymphocytic cells as determined by light microscopy of H&E-stained sections.
Systemic Anti-tumor Effect of Melanoma-Derived IL-6 To determine whether HFH18/IL-6(+) melanomas inhibit the growth of HFH18 melanoma cells at a distant site, mice were inoculated sc with both cell rypes at separate sites and tumor weight was measured at d 30 post injection. Mice co-injected with equal numbers of HFH18 cells (1 X 10 6 ) in one flank and HFH18/IL-6(+) in the opposite flank demonstrate a 40% decrease in the weight ofHFH18 tumors compared to HFH18 tumors in control animals (Fig 7) . Mice co-injected with 1 X 10 6 HFH18 cells in one flank and half as many HFH18/IL-6(+) cells (5 X 10 5 ) in the opposite flank develop HFH18 tumors that are only slightly decreased in size compared to controls. Thus, IL-6 produced by the HFH18/IL-6(+) melanoma cells exerts a systemic growth-inhibitory effect on the growth of distant parental tumors in a dose-dependent manner.
IL-6 Inhibition of Melanoma Growth is Reversed by Injection of Peri tumoral a-IL-6 Antibody To confirm the specificity of the apparent IL-6 -mediated inhibition of melanoma growth, mice were inoculated sc with either the HFH18 cell line or the IL-6-producing HFH18/IL-6(+) cell line and peritumoral injections of 10 fig a-murine IL-6 antibody were administered every 48 h. The treatment ofHFH18 tumors with a-mIL-6 antibody has no effect on tumor volume at d 30 (Fig 8) . In contrast, the treatment of IL-6 -secreting HFH 18 /IL-6(+) tumors with a-mIL-6 antibody results in tumors that grow to the same size as the parental HFH18 cell line at d 30. The control isotype-matched rat immunoglobulin (lg)G administered peritumorally every 48 h has no effect on tumor growth. The augmented growth of the HFH18/IL-6(+) tumors by local injection of neutralizing a-IL-6 antibody provides further evidence that IL-6 is responsible for the decreased it) vivo growth of these melanomas.
Growth of Murine Melanomas in Nude Mice Our studies indicate that IL-6 does not have an apparent direct in vitro inhibitory effect on melanoma cell growth. The observed decrease in in vivo melanoma growth may be mediated by IL-6 through other mecha- Fig 9) . In contrast, nude mice injected with the HFHI8/IL-6(+) cell line develop sc tumors that reach a mean tumor volume of only 2000 mm 3 by d 32 (Figs 9, 10) . Thus, the anti-tumor effect mediated by melanomaderived IL-6 appears not to be dependent on a normal host B-and T-cell immune response.
DISCUSSION
Previous studies indicate that there is significant heterogeneity in the cytokine production profile of malignant melanomas [5, 9] . Using a well controlled animal model, we tested the hypothesis that a specific tumor-derived cytokine may have a profound effect on the growth and progression of cutaneous melanomas. We found that melanoma-derived IL-6 exerts a significant inhibitory effect on subcutaneous melanoma growth and progression. This is consistent with our observation of an inverse relationship between IL-6 production of three B 16-derived murine melanoma cells lines (NP 133, HFHI8, and HFH(M)) and the tumorigenicity of these melanoma cells in syngeneic mice.
IL-6 is a pleotropic cytokine with a wide variety of inflammatory properties. These include the activation ofB and T cells, induction of immunoglobulin production, stimulation of hepatocytes to produce acute phase proteins, and the proliferation of hematopoietic progenitor cells [31] [32] [33] [34] [35] . Additionally, IL-6 activates natural killer (NK) cells [36] and human lymphokine-activated killer (LAK) cells [37) , and serves as a cytotoxic lymphocyte (CTL) differentiation factor [38] .
The role of IL-6 in neoplasia has been the topic of a number of recent reports. IL-6 production has been reported to occur in several different types of malignant human cells including cardiac myxomas, bladder carcinomas, and epidermoid carcinoma cell lines [10, 11] . We have shown that human melanoma cell lines produce IL-6 and that there are distinct differences in the IL-6 production between two human metastatic melanoma cell lines tested [5] . One melanoma cell line constitutively expresses IL-6 mRNA and secretes IL-6 activity, whereas the other cell line does not produce a significant amount of IL-6. In another recent study, it was also noted that one of two human melanoma cell lines tested did not constitutively produce IL-6, but did secrete IL-6 after induction with rIL-la [6J. There is evidence to support both tumor-promoting and tumor-inhibitory properties of IL-6, which may depend A B Figure 10 . Growth of murine melanomas in nude mice. Groups of nude mice were inoculated sc with 1 X 10 6 HFH18/IL-6(+) cells (A) or HFH18 parental cells (B) . These photographs are representative of four mice injected with each cell type evaluated at the 30-d tIme pomt.
both on the tumor cell type and inherent limitations of experimental approaches used [13 -20, 39 -41] .
The role oflL-6 in the biologic behavior of malignant melanoma has been evaluated from different experimental approaches. R:ecent studies have begun to evaluate the effect ofIL-6 on melanocytic cell proliferation. IL-6 is reported to suppress the proliferation of cultured neonatal human melanocytes [42] . Kerbel and co-workers have reported that IL-6 acts as an inhibitory growth factor for melanoma cells removed from lesions of radial growth phase or early vertical growth phase (non-metastatic) melanoma cells, where~s melanoma cell lines from advanced stage cutaneous or metastatic lesions were resistant to this inhibitory effect [8] ' In another recent study, Morinaga et al demonstrated that IL-6 could inhibi~ the in vitro proliferation of an IL-6-producing melanoma cell lme [6] . These results suggested that IL-6 may function as an autocrine antiproliferative factor for c.ert~i~ ~elanoma cells [6] . However, in ?ur studies, we observe no mhlbltlOn of the parental HFH18 cellll11e proliferation in vitro by exogenous murine IL-6. The decreased in vivo growth of transfected, IL-6-producing melanoma cells may thus reflect function(s) ofIL-6 other than direct inhibition of melanoma cell proliferation.
Another recent study also has utilized IL-6 gene transfection to
evaluate melanoma growth in mice [43] . Sun et al have demonstrated decreased tumor growth in Vill O by B16 melanoma cells transfected with the human IL-6 gene [43] . Additionally, the sc growth of non-transfected B 16 cells was reduced in animals receiving daily sc injections of human recombinant IL-6 (5 /lg/d). In tllls study, subcutaneous tumor growth was evaluated only between d 10 and 17 whereas our studies evaluated tumor size between d 0 and 30, and we evaluated survival in separate groups of mice to allow us to evaluate the entire course of melanoma growth. Also, Sun et al noted the IL-6 -transfected melanoma cells formed tumors with distinct histologic featu. res including a prominent stromal matrix, infiltration of inflammatory cells, and fewer blood vessels, whereas no similar histologic changes were noted in our study. This difference could be related to their use of the human IL-6 gene in a murine system whereas we used a murine IL-6 gene in murine tumor cells. The authors speculate that IL-6 may mediate this antitumor response by nonspecific pro inflammatory mechanisms. This study is in agreement with our findings that IL-6 exerts an anti-melanoma effect in vivo.
In addition, we demonstrate that this effect apparently does not require an intact T -and B-cell immunologic system. Our studies indicate that serum IL-6 levels in mice bearing HFH18/IL-6(+) cells were significantly higher than in mice bearing HFH18 parental or HFH18/IL-6(-) tumors even though actual tumor burden was much less in these animals. An increase in serum IL-6 with a large tumor cell burden has been previously reported in various types of neoplasms [29, 30] . The tumor burden of mice bearing HFH18/IL-6(+) tumors was significantly less than that of mice bearing HFH18 parental or HFH18/IL-6(-) melanomas at all time points after tumor cell inoculation. These results indicate that the mice injected with HFH18/IL-6(+) melanoma cells have significantly higher levels of serum IL-6 compared to control animals. It is likely that IL-6 production by the injected HFH18/IL-6(+) cells was primarily responsible for the elevated serum IL-6 levels in these mice.
Thus, we have demonstrated that IL-6 production results in decreased growth and progression of sc malignant melanoma. This provides further evidence for the role of this multifunctional cytokine in the biology of this neoplasm. The experimental model developed in this study facilitates the evaluation of the complex autocrine, paracrine, and systemic effects of melanoma cell-derived cytokines in melanoma pathogenesis. Experiments are under way to further evaluate the mechanism by which IL-6 exerts this in vivo effect. The heterogeneity of cytokine production by human malignant melanomas, however, suggests the need to evaluate additional cytokines or combinations of cytokines using an in vivo model.
